Phase 2 Stomach Cancer Trial, Recruiting NCT07655024 Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT07655024
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed through laboratory testing of tissue samples
  • People whose cancer has been assessed by a surgeon as advanced and not able to be removed through surgery
  • People for whom surgery is not suitable due to general physical frailty or other existing health conditions
  • People who are expected to have a survival period of at least 3 months

Who may not be able to join:

  • People who have a primary malignant tumour (a cancer that originated elsewhere in the body — confirm with trial site)
  • People who have a blockage in the digestive tract caused by growths in the lower part of the stomach, the small intestine just after the stomach, the pancreas, or other nearby organs
  • People who have an active serious infection, severely reduced liver or kidney function, or a condition affecting the blood's ability to clot
  • People who have a known allergy to the study drugs, or who have a diagnosed mental health disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Quanda Liu, PhD, Guanganmen Hospital

Phone: +86 15010797262

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
1 January 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The quality of life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov